Fate Therapeutics, Inc. FATE

FATE Company Overview

Fate Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of programmed cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). The company operates within the biotechnology, oncology, and cell therapy industries, with a primary emphasis on off-the-shelf immune cell therapies designed to treat cancer and immune disorders. Its core product candidates include natural killer (NK) cell and T-cell therapies engineered for improved persistence, targeting, and manufacturing scalability. The company’s revenue has historically been generated primarily through collaboration agreements, research funding, licensing arrangements, and equity investments from strategic partners, rather than commercial product sales.

The company has positioned itself as a developer of scalable allogeneic cell therapies using renewable master iPSC lines, which differentiates its platform from autologous cell therapy approaches that rely on patient-derived material. Fate Therapeutics was founded in 2007 and is headquartered in San Diego, California. Over time, the company evolved from a broader stem cell modulation and regenerative medicine focus into a concentrated cellular immunotherapy platform company centered on engineered iPSC-derived cancer therapies. Public disclosures in SEC filings and investor presentations indicate that the company has prioritized manufacturing consistency, genetic engineering capabilities, and off-the-shelf product accessibility as strategic advantages.